Atrial Fibrillation September 5, 2024
Nearly a year after Bayer halted its OCEANIC-AF trial, the study’s ESC 2024 presentation revealed new insights into asundexian’s AFib stroke-prevention challenges and what they might mean for Factor XI inhibitors.
Pharmaceuticals September 3, 2024
Alylam’s vutrisiran dominated early ESC 2024 headlines and conversations, after full results from the Phase 3 HELIOS-B trial highlighted its significant impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Cholesterol Reduction August 29, 2024
Novartis’ Leqvio took a major step towards establishing itself as an LDL-C monotherapy, after topline results from the V-MONO study revealed significant LDL-C reductions in patients with low or moderate ASCVD risks.